MYC oncogene in myeloid neoplasias

Abstract

MYC is a transcription factor that regulates many critical genes for cell proliferation, differentiation, and biomass accumulation. MYC is one of the most prevalent oncogenes found to be altered in human cancer, being deregulated in about 50 % of tumors. Although MYC deregulation has been more frequently associated to lymphoma and lymphoblastic leukemia than to myeloid malignancies, a body of evidence has been gathered showing that MYC plays a relevant role in malignancies derived from the myeloid compartment. The myeloid leukemogenic activity of MYC has been demonstrated in different murine models. Not surprisingly, MYC has been found to be amplified or/and deregulated in the three major types of myeloid neoplasms: acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, including chronic myeloid leukemia. Here, we review the recent literature describing the involvement of MYC in myeloid tumors.

<b><i>MYC</i></b> Amplification in the Form of Ring Chromosomes 8 in Acute Myeloid Leukemia with t(11;16)(q13;p11.2)

“…We also demonstrated MYC protein overexpression at the diagnosis of AML and almost negative expression in hematological and cytogenetic CR. The MYC protein plays a pivotal role in regulating normal hematopoiesis, and its deregulation may transform hematopoietic cells by stimulating proliferation and blocking differentiation [Delgado et al, 2013]. Our results clearly indicate that MYC protein expression correlates with MYC gene amplification during the clinical course, and suggest that they play a crucial role in leukemogenesis.…”

Posttranscriptional regulation of c-Myc expression in adult murine HSCs during homeostasis and interferon-α-induced stress response

“…This is likely to be important beyond the scope of normal stem cell biology, because c-Myc is critical in other stem cells and is one of the most potent oncogenes frequently deregulated in hematologic and solid malignancies. [13][14][15][16][17] …”

Acute toxicity of nickel nanoparticles in rats after intravenous injection

“…Major advances have taken place in diagnostics and treatment with the development of improved contrast agents [1][2][3][4][5] and drug delivery vehicles. [6][7][8] The use of metallic nanoparticles and compounds generated with metallic nanoparticles have been paramount to these advances. Nickel (Ni) and Ni compound nanoparticles are among the compounds being investigated; for example, nickel ferrite (Ni-Fe 2 O 4 ).…”